MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
This issue of ‘anabolic and catabolic signals’ mainly contains challenging reviews on the control of muscle mass. Two papers in this issue are devoted to recent progress in the elucidation of signaling pathways that control muscle size (Glass, pp. 225–229; McCarthy and Esser, pp. 230–235). Accordingly, the authors review the different mechanisms regulating the expression of two ubiquitin–protein ligases (E3) called MAFbx/Atrogin-1 and MuRF-1. These E3 figure prominently in recent research, as early work led to the hope that they might serve as sensitive biomarkers related to muscle wasting and to the specific rate of muscle protein degradation, an important process but one that is dauntingly difficult to measure in vivo. However, recent findings concerning MAFbx/Atrogin-1 also reveal unexpected problems of interpretation. MAFbx/Atrogin-1 and MuRF1 were identified in 2001 in the laboratories of both Glass [1] and Goldberg [2]. These studies nicely demonstrated that the two E3 were muscle-specific, their expression was increased by at least 6–10 times in several catabolic conditions (muscle disuse, hind limb suspension, denervation, and glucocorticoid or interleukin-1 treatment [1], fasting, cancer cachexia, diabetes, and renal failure [2]), and knockout mice for either E3 were partially resistant to muscle wasting [1]. At present, it has been already established that the ubiquitin–proteasome system (UPS) played a major role in muscle wasting and more particularly in the breakdown of myofibrillar proteins. The two identified E3 were critical components of the UPS (E3 recognize specific substrates for polyubiquitination that are subsequently targeted for breakdown by the 26S proteasome), were muscle-specific, and played a key role in muscle wasting. Accordingly, investigators were quick to use increased expression of either gene as a convenient marker of enhanced muscle protein breakdown. These studies confirmed that both MAFbx/Atrogin-1 and MuRF1 are overexpressed in numerous catabolic conditions. Moreover, significant advances have been made in elucidating the signaling pathways that control the expression of the two E3 and result in muscle atrophy [see Glass (pp. 225–229) and [3,4]]. Such studies are of importance for proposing new strategies to prevent or limit muscle wasting. Subsequently, MAFbx/Atrogin-1 was the subject of reports by different laboratories [5–7] showing no correlation between the expression of MAFbx/Atrogin-1 and rates of protein breakdown both in rat muscles [5,6] and C2C12 myotubes [7]. Numerous papers now are pointing out this discrepancy, including human studies [for recent reviews, see Murton and Greenhaff (pp. 249–254) and [8]]. That a more serious issue was raised when the MyoD transcription factor was reported to be a MAFbx/Atrogin-1 substrate [9] is important, as proteolysis of this transcription factor for muscle proteins would be expected to influence muscle differentiation and protein synthesis. In 2007, the group of David J. Glass provided evidence that myosin heavy chain (MHC), a major myofibrillar protein, is recognized by MuRF-1 in muscle cells [10]. More recent in-vivo experiments have demonstrated that not only MHC but also other myofibrillar proteins are targeted for breakdown by the proteasome in a MuRF-1-dependent fashion [11]. These findings are in perfect agreement with a major role of MuRF-1 in skeletal muscle proteolysis. Interestingly, however, a role for MuRF-1 in protein synthesis has also been recently reported [12,13]. Where are we with the MAFbx/Atrogin-1 substrates? The only identified substrates of this E3 have been characterized by the group of Serge Leibovitch and to date include MyoD [9,14] and the eukaryotic initiation factor of protein synthesis eIF3-f [15–17]. These two proteins play key roles in the control of protein synthesis and not in the breakdown of muscle proteolysis. Leibovitch and coworkers recently provided strong further evidence that MAFbx/Atrogin-1 modulated muscle size by regulating protein synthesis. Firstly, in cultured myotubes undergoing atrophy, MAFbx/Atrogin-1 expression increased, leading to a cytoplasmic-nuclear shuttling of E3 and to selective MyoD suppression. Conversely, transfection of myotubes with sh-RNA-mediated MAFbx/Atrogin-1 gene silencing (shRNAi) inhibited atrophy-dependent MyoD breakdown. Overexpression of a MyoD mutant lacking MAFbx/Atrogin-1-mediated ubiquitination prevented atrophy of both mouse primary myotubes and skeletal muscle fibers in vivo[14]. Secondly, in MAFbx/Atrogin-1-induced atrophy, the degradation of eIF3-f suppressed S6K1 activation by mTOR [17]. By contrast, an eIF3-f mutant insensitive to MAFbx/Atrogin-1 polyubiquitination exhibited persistent phosphorylation of S6K1 and rpS6. A conserved motif in eIF3-f connected the mTOR/raptor complex, which phosphorylates S6K1 and regulates downstream effectors of mTOR and Cap-dependent translation initiation in terminal muscle differentiation. The authors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice
Cai, D., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B.-C., Lidov, H. G. W., Hasselgren, P.-O., Frontera, W. R., Lee, J., Glass, D. J., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.027 · Cited by 1,367
The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle
Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.009 · Cited by 683
Cited by
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Fearon, K. C. H., Glass, D. J., & Guttridge, D. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.011 · Cited by 1,205
The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill
Friedrich, O., Reid, M. B., Van den Berghe, G., Vanhorebeek, I., Hermans, G., Rich, M. M., & Larsson, L. (2015) · Physiological Reviews · doi:10.1152/physrev.00028.2014 · Cited by 396
Dodson, S., Baracos, V. E., Jatoi, A., Evans, W. J., Cella, D., Dalton, J. T., & Steiner, M. S. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061509-131248 · Cited by 319
“By identifying specific mediators of muscle atrophy, recent studies may support new therapeutic strategies to prevent or attenuate muscle wasting, as well as the identification of sensitive biomarkers of protein degradation (29).”
Self-citationBindels, L. B., Beck, R., Schakman, O., Martin, J. C., De Backer, F., Sohet, F. M., Dewulf, E. M., Pachikian, B. D., Neyrinck, A. M., Thissen, J.-P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037971 · Cited by 278
Schefold, J. C., Bierbrauer, J., & Weber-Carstens, S. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0010-6 · Cited by 268
Metadata
- Authors
- Attaix, D., & Baracos, V. E.
- Venue
- Current Opinion in Clinical Nutrition and Metabolic Care
- Published
- 2010-05
- Volume
- 13
- Issue
- 3
- Pages
- 223-224
- ISSN
- 1363-1950 (ISSN-L)
- OpenAlex
- W2039434704
- Cited by
- 67
- References
- 4
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.